Prasugrel
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Prasugrel: From Antiplatelet Therapy to Pulmonary Hypertension
One-Sentence Summary
Prasugrel is a P2Y12 platelet receptor antagonist, internationally used as an antiplatelet agent in the setting of acute coronary syndrome and percutaneous coronary intervention. The TxGNN model predicts it may be effective for Pulmonary Hypertension, but this direction is currently supported only by 2 clinical trials and 2 publications, none of which directly evaluate prasugrel in pulmonary hypertension.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in this dataset (internationally known as an antiplatelet agent for acute coronary syndrome/PCI — see note below) |
| Predicted New Indication | Pulmonary Hypertension |
| TxGNN Prediction Score | 99.88% |
| Evidence Level | L4 |
| UK Market Status | Not marketed (per current dataset) |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on widely established pharmacological knowledge, Prasugrel is a thienopyridine-class, irreversible P2Y12 receptor antagonist that inhibits ADP-mediated platelet activation and aggregation; its efficacy in acute coronary syndrome and post-PCI stent thrombosis prevention is well established internationally.
The predicted link to pulmonary hypertension is mechanistically indirect. Pulmonary hypertension — particularly chronic thromboembolic pulmonary hypertension (CTEPH) — involves thrombotic occlusion of the pulmonary vasculature, and antiplatelet inhibition of platelet activation could theoretically contribute to reducing thrombus burden in this specific subtype. However, first-line pharmacological management of thromboembolic pulmonary hypertension is anticoagulation, not antiplatelet therapy, so the mechanistic rationale remains largely theoretical rather than directly supported by disease-specific pathophysiology.
Consistent with this, none of the identified clinical trials or literature evaluate prasugrel specifically in pulmonary hypertension populations; the supporting evidence instead relates to adjacent but distinct clinical contexts (atrial fibrillation anticoagulation, cancer-associated thrombosis). The prediction should therefore be regarded as hypothesis-generating rather than evidence-supported at this stage.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT03993119 | N/A | Completed | 500 | Observational, cross-sectional study describing NOAC management in elderly patients with non-valvular atrial fibrillation in Spain; does not evaluate prasugrel or pulmonary hypertension (relevance grade C). |
| NCT04846556 | N/A | Completed | 300 | Retrospective study on eligibility of cancer-associated thrombosis patients for the CARAVAGGIO anticoagulation trial; does not evaluate prasugrel or pulmonary hypertension (relevance grade C). |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 21241206 | 2011 | Cohort | Current Medical Research and Opinion | Evaluated factors associated with clopidogrel use/adherence after PCI in acute coronary syndrome; prasugrel mentioned only as a guideline comparator, not studied in pulmonary hypertension. |
| 34713782 | 2021 | Cohort | Kardiologiia | ACTIV SARS-CoV-2 registry analysis of background chronic disease therapy on COVID-19 mortality; not specific to prasugrel or pulmonary hypertension. |
UK Market Information
No marketing authorisation records are available in this dataset (market status: Not marketed; total licences: 0). No product name, dosage form, or approved indication data can be reported at this time.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: Key warnings, contraindications, and drug interaction data are flagged as a blocking data gap (DG001) in this evidence pack and could not be retrieved from the regulatory source at the time of this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic link between prasugrel and pulmonary hypertension is theoretical, and the available clinical trials and literature (relevance grade C) do not directly evaluate prasugrel in this indication. Combined with a blocking safety data gap and the absence of UK marketing authorisation records, the evidence base is insufficient to progress beyond hypothesis stage (S1).
To proceed, the following is needed:
- SmPC-level warnings, contraindications, and drug interaction data (resolve DG001)
- Confirmed mechanism of action documentation specific to prasugrel (resolve DG002)
- Clinical trials or observational studies directly evaluating prasugrel (or thienopyridine-class agents) in pulmonary hypertension, particularly CTEPH populations
- Clarification of current UK marketing authorisation status for prasugrel
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.